Gracell Biotechnologies Stock Price, News & Analysis (NASDAQ:GRCL) $5.29 +0.42 (+8.62%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$4.77▼$5.3150-Day Range$2.43▼$5.4052-Week Range$1.40▼$6.99Volume257,122 shsAverage Volume352,986 shsMarket Capitalization$384.48 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Gracell Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside158.3% Upside$13.67 Price TargetShort InterestHealthy1.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.92) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector561st out of 949 stocksPharmaceutical Preparations Industry269th out of 442 stocks 3.5 Analyst's Opinion Consensus RatingGracell Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, Gracell Biotechnologies has a forecasted upside of 158.3% from its current price of $5.29.Amount of Analyst CoverageGracell Biotechnologies has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.29% of the float of Gracell Biotechnologies has been sold short.Short Interest Ratio / Days to CoverGracell Biotechnologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gracell Biotechnologies has recently increased by 2.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGracell Biotechnologies does not currently pay a dividend.Dividend GrowthGracell Biotechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRCL. Previous Next 2.7 News and Social Media Coverage News SentimentGracell Biotechnologies has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Gracell Biotechnologies this week, compared to 1 article on an average week.Search Interest6 people have searched for GRCL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gracell Biotechnologies insiders have not sold or bought any company stock.Percentage Held by Insiders28.00% of the stock of Gracell Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gracell Biotechnologies are expected to decrease in the coming year, from ($0.92) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gracell Biotechnologies is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gracell Biotechnologies is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGracell Biotechnologies has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gracell Biotechnologies Stock (NASDAQ:GRCL)Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.Read More GRCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRCL Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comEvercore ISI Initiates Coverage on Gracell Biotechnologies (NASDAQ:GRCL)November 29, 2023 | markets.businessinsider.comBuy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy AdvancementsDecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | msn.comEvercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform RecommendationNovember 27, 2023 | marketwatch.comGracell Biotechnologies Shares Rise 9%, FDA Clears Application for Lupus TreatmentNovember 27, 2023 | markets.businessinsider.comGracell Biotechnologies: FDA Clears IND Application For Phase 1/2 Trial Of FasTCAR-T GC012FNovember 27, 2023 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNovember 23, 2023 | finance.yahoo.comWhat Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 23, 2023 | finance.yahoo.comDoes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?November 16, 2023 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNovember 16, 2023 | finance.yahoo.comGracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNovember 14, 2023 | markets.businessinsider.comPositive Outlook for Gracell Biotechnologies: Promising Translational Data and Financial Stability Backs Buy RatingNovember 14, 2023 | markets.businessinsider.comGracell Biotechnologies: Promising Developments in Systemic Lupus Erythematosus Treatment Augment Buy RatingNovember 14, 2023 | finance.yahoo.comQ3 2023 Gracell Biotechnologies Inc Earnings CallNovember 13, 2023 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comGracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate UpdateNovember 10, 2023 | benzinga.comA Preview Of Gracell Biotechnologies's EarningsNovember 9, 2023 | finance.yahoo.comShould You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings?November 8, 2023 | finance.yahoo.comGracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards ProgramNovember 2, 2023 | finance.yahoo.comGracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & ExpositionOctober 31, 2023 | finance.yahoo.comGracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOctober 19, 2023 | msn.comStifel Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Buy RecommendationOctober 19, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Gracell BiotechnologiesSeptember 27, 2023 | finance.yahoo.comGracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response RateSeptember 26, 2023 | finance.yahoo.comGracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple MyelomaSeptember 19, 2023 | finance.yahoo.comGracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science LeadersSee More Headlines Receive GRCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRCL CUSIPN/A CIK1826492 Webwww.gracellbio.com Phone86-512-6262-6701FaxN/AEmployees314Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+158.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.40% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.02 Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$60,000.00 Price / Sales6,407.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book1.73Miscellaneous Outstanding Shares72,680,000Free Float52,328,000Market Cap$384.48 million OptionableNot Optionable Beta-1.32 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Wei Cao BM (Age 64)Ph.D., Founder, Chairman & CEO Dr. Yili Xie M.B.A. (Age 52)Ph.D., Chief Financial Officer Dr. Samuel Suhua Zhang M.B.A. (Age 55)Ph.D., Chief Business Officer Dr. Wendy Li M.D. (Age 64)Chief Medical Officer Ms. Erin LiExecutive OfficerKey CompetitorsImmunomeNASDAQ:IMNMuniQureNASDAQ:QURENature's Sunshine ProductsNASDAQ:NATRHarrow HealthNASDAQ:HROWIGM BiosciencesNASDAQ:IGMSView All CompetitorsInstitutional OwnershipAdage Capital Partners GP L.L.C.Bought 850,000 shares on 11/15/2023Ownership: 1.170%Pivotal bioVenture Partners Investment Advisor LLCBought 1,375,000 shares on 11/14/2023Ownership: 1.892%Schonfeld Strategic Advisors LLCBought 215,706 shares on 11/14/2023Ownership: 1.045%Fred Alger Management LLCSold 34,234 shares on 11/14/2023Ownership: 0.085%Tower Research Capital LLC TRC Bought 23,417 shares on 11/14/2023Ownership: 0.047%View All Institutional Transactions GRCL Stock Analysis - Frequently Asked Questions Should I buy or sell Gracell Biotechnologies stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRCL shares. View GRCL analyst ratings or view top-rated stocks. What is Gracell Biotechnologies' stock price target for 2024? 6 analysts have issued 12 month price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 158.3% from the stock's current price. View analysts price targets for GRCL or view top-rated stocks among Wall Street analysts. How have GRCL shares performed in 2023? Gracell Biotechnologies' stock was trading at $2.30 at the beginning of 2023. Since then, GRCL shares have increased by 130.0% and is now trading at $5.29. View the best growth stocks for 2023 here. When is Gracell Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our GRCL earnings forecast. How were Gracell Biotechnologies' earnings last quarter? Gracell Biotechnologies Inc. (NASDAQ:GRCL) issued its quarterly earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.18. The firm earned $0.06 million during the quarter. When did Gracell Biotechnologies IPO? (GRCL) raised $150 million in an IPO on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO. Who are Gracell Biotechnologies' major shareholders? Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (14.97%), Pivotal bioVenture Partners Investment Advisor LLC (1.89%), Adage Capital Partners GP L.L.C. (1.17%), Schonfeld Strategic Advisors LLC (1.04%), Barclays PLC (0.43%) and Fred Alger Management LLC (0.08%). How do I buy shares of Gracell Biotechnologies? Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GRCL) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gracell Biotechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.